ABT

Abbott Labs (ABT) Stock Slips Despite Solid Q4 Earnings

By Karl Utermohlen, InvestorPlace Writer
Abbott Labs (ABT) stock was down more than 2% on Wednesday despite the fact that the company's fourth-quarter earnings reached expectations.

5 Must-See Stock Charts for Thursday: ABT, IBM, SBUX, PZZA

By Bret Kenwell, InvestorPlace Contributor
IBM, Abbott Labs, Papa John's, Starbucks and Disney round out our must-see stock charts for Thursday. Here's why.

All Signals Are Positive for Buying Abbott Laboratories

By Chris Lau, InvestorPlace Contributor
Abbott is about to report another quarter to cap 2018's strong annual performance. ABT stock also offers a dividend for income investors.

3 Back-of-the-Shelf Consumer Stocks With Growth and Income

By Will Healy, InvestorPlace Contributor
These consumer stocks offer generous, growing dividends and should return to a growth trajectory based on new business lines.

3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories

By James Brumley, InvestorPlace Feature Writer
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.

5 Top Stock Trades for Thursday

By Bret Kenwell, InvestorPlace Contributor
A buyout for Ceasars? Earnings from Netflix, Abbott and Lam Research -- we've got it all covered in our top stock trades article.

ABT Stock Dips Following Q3 Earnings Results

By William White, InvestorPlace Writer
ABT stock was down on Wednesday after the healthcare company released its earnings report for the third quarter of the year.

The 7 Best Long-Term Stocks for Risk-Off Investors

By Will Ashworth, InvestorPlace Contributor
The short-term nature of the stock markets makes it hard for companies to think bigger picture -- but these seven best long-term stocks do. 

10 Dividend Aristocrats You Never Have to Worry About

By James Brumley, InvestorPlace Feature Writer
There are dividend stocks, and then there are dividend aristocrats. These ten names are the income producers you rarely have to worry about.

RBC Capital Markets: 10 Leaders and Laggards for 2025

By Harriet Lefton, Writer, TipRanks
We take a closer look at 10 stocks RBC Capital has pinpointed as the leaders and laggards of the future. These are the stocks that are set to outperform in 2025, but also the stocks facing the biggest risks from our ever-changing society.

Abbott Laboratories Stock Gets a Boost From Q2 Earnings Beat

By William White, InvestorPlace Writer
Abbott Laboratories (ABT) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018.

3 Big Stock Charts for Wednesday: United Technologies, Abbott Laboratories and Leggett & Platt

By James Brumley, InvestorPlace Feature Writer
Stock charts of United Technologies, Abbott Laboratories and Leggett & Platt have earned a closer look as bullish trading prospects this morning.

Abbott Laboratories Stock Slips Despite Earnings Beat

By William White, InvestorPlace Writer
Abbott Laboratories (ABT) stock as down on Wednesday despite the health care company reporting an earnings beat for the first quarter of 2018.

At $ 59.460, Abbott Laboratories (ABT) a Buy

By Portfolio Grader
The Buy for Abbott Laboratories (ABT) this week is based on the latest relative pricing of its shares and market intelligence.

Abbott Laboratories (ABT) a Buy This Week

By Portfolio Grader
The Buy for Abbott Laboratories (ABT) this week is based on the latest relative pricing of its shares and news.

5 Cheap Dividend Stocks With Growing Payouts

By Lawrence Meyers, InvestorPlace Contributor
With interest rates still low and the market possibly overvalued, cheap dividend stocks are a good choice for retirement and income investors.

7 ‘Strong Buy’ Stocks That Look Cheap Right Now

By Harriet Lefton, Writer, TipRanks
With recent market fluctuations, these 7 stocks now make particularly compelling investing opportunities -- and each boasts a Street consensus rating of 'Strong Buy.'

Abbott Laboratories (ABT) a Buy at recent price of $63.22, on Robust Earnings Momentum

By Portfolio Grader
Portfolio Grader currently ranks ABT as a Buy. This analytical tool evaluates stocks by employing proprietary fundamental and quantitative analytical. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 4 months.

5 Soaring ‘Strong Buy’ Stocks Ahead of Earnings Season

By Harriet Lefton, Writer, TipRanks
Here are five stellar stocks to keep a close eye on as we head deeper into earnings season. All these stocks are due to report earnings in the next couple of weeks. You can feel good about these stock picks as each of these five stocks has a 'Strong Buy' consensus rating from the Street's best-performing analysts.
Load More